Chronic Hepatitis B

HBV Response To Lamivudine Predicted In First Three Months Of Therapy

Published in Hepatitis Weekly, May 21st, 2001

by Sonia Nichols, senior medical writer - Viral activity during the first three months of therapy is an essential factor in the ultimate response of chronic hepatitis B patients to lamivudine therapy.

Lamivudine, a drug commonly used for treating patients with hepatitis B virus (HBV), is not effective in all patients. A new study proposes that by quantifying HBV levels and examining serum samples for virus mutations, physicians could get an early indication of whether lamivudine therapy will be effective in patients with chronic hepatitis B.

Maria Buti, lead investigator of the current study, and coworkers at the Universidad Valle de Hebron in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-05-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry